The Efficacy and Applicability of Chimeric Antigen Receptor (Car) T Cell-Based Regimens for Primary Bone Tumors: A Comprehensive Review of Current Evidence Publisher



Barzegari A¹ ; Salemi F² ; Kamyab A³ ; Aratikatla A⁴ ; Nejati N⁵ ; Valizade M⁶ ; Eltouny E⁷ ; Ebrahimi A⁷
Source: Journal of Bone Oncology Published:2024

Abstract

Primary bone tumors (PBT), although rare, could pose significant mortality and morbidity risks due to their high incidence of lung metastasis. Survival rates of patients with PBTs may vary based on the tumor type, therapeutic interventions, and the time of diagnosis. Despite advances in the management of patients with these tumors over the past four decades, the survival rates seem not to have improved significantly, implicating the need for novel therapeutic interventions. Surgical resection with wide margins, radiotherapy, and systemic chemotherapy are the main lines of treatment for PBTs. Neoadjuvant and adjuvant chemotherapy, along with emerging immunotherapeutic approaches such as chimeric antigen receptor (CAR)-T cell therapy, have the potential to improve the treatment outcomes for patients with PBTs. CAR-T cell therapy has been introduced as an option in hematologic malignancies, with FDA approval for several CD19-targeting CAR-T cell products. This review aims to highlight the potential of immunotherapeutic strategies, specifically CAR T cell therapy, in managing PBTs. © 2024 The Author(s)